Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Reduced serologic response to mumps, measles, and rubella vaccination in patients treated with intravenous immunoglobulin for Kawasaki disease.

Tacke CE, Smits GP, van der Klis FR, Kuipers IM, Zaaijer HL, Kuijpers TW.

J Allergy Clin Immunol. 2013 Jun;131(6):1701-3. doi: 10.1016/j.jaci.2013.01.045. Epub 2013 Mar 14. No abstract available.

PMID:
23498596
[PubMed - indexed for MEDLINE]
2.

Kawasaki disease: a maturational defect in immune responsiveness.

Kuijpers TW, Wiegman A, van Lier RA, Roos MT, Wertheim-van Dillen PM, Pinedo S, Ottenkamp J.

J Infect Dis. 1999 Dec;180(6):1869-77.

PMID:
10558943
[PubMed - indexed for MEDLINE]
Free Article
3.

Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P.

Eur J Pediatr. 2012 Mar;171(3):463-70. doi: 10.1007/s00431-011-1569-4. Epub 2011 Sep 21.

PMID:
21935584
[PubMed - indexed for MEDLINE]
4.

Kawasaki disease and human parvovirus B19 antibody: role of immunoglobulin therapy.

Fukushige J, Takahashi N, Ueda K, Okada K, Miyazaki C, Maeda Y.

Acta Paediatr Jpn. 1995 Dec;37(6):758-60. No abstract available.

PMID:
8775567
[PubMed - indexed for MEDLINE]
5.

Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease.

Shrestha S, Wiener HW, Olson AK, Edberg JC, Bowles NE, Patel H, Portman MA.

J Allergy Clin Immunol. 2011 Sep;128(3):677-80. doi: 10.1016/j.jaci.2011.04.027. Epub 2011 May 20. No abstract available.

PMID:
21601260
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.

Shiraishi T, Yamamoto T.

Pediatr Dermatol. 2013 May-Jun;30(3):e30-1. doi: 10.1111/j.1525-1470.2011.01717.x. Epub 2012 Feb 3.

PMID:
22304420
[PubMed - indexed for MEDLINE]
7.

The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.

Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K.

N Engl J Med. 1994 Nov 24;331(21):1397-402.

PMID:
7969278
[PubMed - indexed for MEDLINE]
Free Article
8.

MMR vaccination: new thought.

Deshmukh V.

Indian Pediatr. 2006 Jun;43(6):555-6. No abstract available.

PMID:
16820670
[PubMed - indexed for MEDLINE]
Free Article
9.

Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.

Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.

Pediatr Infect Dis J. 2005 Dec;24(12):1083-8.

PMID:
16371870
[PubMed - indexed for MEDLINE]
10.

Measles, mumps and rubella: control by vaccination.

van Druten JA, de Boo T, Plantinga AD.

Dev Biol Stand. 1986;65:53-63.

PMID:
3556777
[PubMed - indexed for MEDLINE]
11.

Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12.

PMID:
20448530
[PubMed - indexed for MEDLINE]
Free Article
12.

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

Nolan T, McIntyre P, Roberton D, Descamps D.

Vaccine. 2002 Dec 13;21(3-4):281-9.

PMID:
12450703
[PubMed - indexed for MEDLINE]
13.

Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

Wellington K, Goa KL.

Drugs. 2003;63(19):2107-26. Review.

PMID:
12962524
[PubMed - indexed for MEDLINE]
14.

Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.

Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, Abdinia B, Shamshiri AR, Khairkhah M, Shekari Ebrahimabad H, Karimi A.

Arch Iran Med. 2013 Jan;16(1):38-41. doi: 013161/AIM.0012.

PMID:
23273235
[PubMed - indexed for MEDLINE]
Free Article
15.

Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin.

Miura M, Katada Y, Ishihara J.

Eur J Pediatr. 2004 Jan;163(1):25-9. Epub 2003 Nov 18.

PMID:
14624356
[PubMed - indexed for MEDLINE]
16.

Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.

Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.

J Infect Dis. 2004 May 1;189 Suppl 1:S116-22.

PMID:
15106100
[PubMed - indexed for MEDLINE]
Free Article
18.

Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.

Poethko-Müller C, Mankertz A.

PLoS One. 2012;7(8):e42867. doi: 10.1371/journal.pone.0042867. Epub 2012 Aug 6.

PMID:
22880124
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A new combination vaccine for measles, mumps, rubella and varicella.

Zareba G.

Drugs Today (Barc). 2006 May;42(5):321-9. Review.

PMID:
16801995
[PubMed - indexed for MEDLINE]
20.

Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.

Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L, Cesaro S.

Cancer. 2004 Aug 1;101(3):635-41.

PMID:
15274078
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk